Home Featured Page 24

Featured

Latest

Toad, Truth, and the Trouble with 5-MeO: Why Bufo alvarius Needs Our Protection

One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect

From Huxley to Heffter: Mark Geyer Reflects on a Life in Psychedelic Research

Advanced Shadow Work and Psychedelic Integration: A Jungian Path to Wholeness

Healing Psychedelics: Where Science Meets Spirit

Pα+ Psychedelic Bulletin #175: atai Sells a Third of Compass Stake;...

The Hidden Roots of Australia’s Psychedelic Underground

The Globalization of Ayahuasca, Psychedelic Parenting, and the Power of Ceremony

The Psychedelics Lobby: Tracking Federal Lobbying by Psychedelics Companies and Nonprofits

Tripped: The Connection Between LSD, Nazi Germany, and MKUltra

Pα+ Psychedelic Bulletin #174: Psilocybin Outperforms Escitalopram After 6 Months… or...

Ancestral Knowledge: Why Understanding the Ancient is Crucial for Western Psychedelic...

Intention, Making Space for Integration, and Finding Joy in the Mundane

The Psychedelic News Feed: March 4, 2024 – September 1, 2024

1...232425...295 Page 24 of 295

Toad, Truth, and the Trouble with 5-MeO: Why Bufo alvarius Needs...

One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Toad, Truth, and the Trouble with 5-MeO: Why Bufo alvarius Needs Our Protection

One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect

Harry Pack NFT – Last Call

From Huxley to Heffter: Mark Geyer Reflects on a Life in Psychedelic Research

Advanced Shadow Work and Psychedelic Integration: A Jungian Path to Wholeness

Healing Psychedelics: Where Science Meets Spirit

Pα+ Psychedelic Bulletin #175: atai Sells a Third of Compass Stake;...

The Hidden Roots of Australia’s Psychedelic Underground

The Globalization of Ayahuasca, Psychedelic Parenting, and the Power of Ceremony

The Psychedelics Lobby: Tracking Federal Lobbying by Psychedelics Companies and Nonprofits

Tripped: The Connection Between LSD, Nazi Germany, and MKUltra

Pα+ Psychedelic Bulletin #174: Psilocybin Outperforms Escitalopram After 6 Months… or...

Ancestral Knowledge: Why Understanding the Ancient is Crucial for Western Psychedelic...

Intention, Making Space for Integration, and Finding Joy in the Mundane

The Psychedelic News Feed: March 4, 2024 – September 1, 2024

EDITOR PICKS

Toad, Truth, and the Trouble with 5-MeO: Why Bufo alvarius Needs...

One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect

Harry Pack NFT – Last Call

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY